Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
McKesson
Express Scripts
Mallinckrodt

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for BCT197


Email this page to a colleague

« Back to Dashboard

What is the drug development status for BCT197?

BCT197 is an investigational drug.

There have been 5 clinical trials for BCT197. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2016.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Mereo BioPharma, Novartis Pharmaceuticals, and Novartis.

There are fourteen US patents protecting this investigational drug and two hundred and thirty international patents.

Recent Clinical Trials for BCT197
TitleSponsorPhase
The Effect of Itraconazole on BCT197 Exposure in Healthy Male ParticipantsMereo BioPharmaPhase 1
The Effect of Azithromycin on BCT197 Exposure in Healthy Male VolunteersMereo BioPharmaPhase 1
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseaseMereo BioPharmaPhase 2

See all BCT197 clinical trials

Clinical Trial Summary for BCT197

Top disease conditions for BCT197
Top clinical trial sponsors for BCT197

See all BCT197 clinical trials

US Patents for BCT197

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BCT197 ⤷  Try it Free JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) ⤷  Try it Free
BCT197 ⤷  Try it Free Fused imidazo-piperidine JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) ⤷  Try it Free
BCT197 ⤷  Try it Free P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (Cambridge, MA) ⤷  Try it Free
BCT197 ⤷  Try it Free JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) ⤷  Try it Free
BCT197 ⤷  Try it Free Methods of treatment using a JAK inhibitor compound THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BCT197

Drugname Country Document Number Estimated Expiration Related US Patent
BCT197 Argentina AR111241 2037-03-09 ⤷  Try it Free
BCT197 Argentina AR111242 2037-03-09 ⤷  Try it Free
BCT197 Australia AU2018231032 2037-03-09 ⤷  Try it Free
BCT197 Australia AU2018231035 2037-03-09 ⤷  Try it Free
BCT197 Brazil BR112019018648 2037-03-09 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Baxter
McKesson
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.